Sildenafil citrate, commonly known by the brand name, is a prescription-only medicine used to treat erectile dysfunction (ED) in adult men. It works by improving blood flow to the penis, helping to achieve and maintain an erection during sexual activity.
Sildenafil is available in 25mg, 50mg, and 100mg strengths.
Sildenafil has been shown to be effective in up to 80% of men with ED, with effects typically noticeable within 30 to 60 minutes, and lasting for up to 4–5 hours.
Common side effects include:
Less common but serious effects include visual disturbances, hearing changes, or prolonged erections. Seek medical attention if severe or persistent side effects occur.
Sildenafil should not be used by those:
Inform your doctor of all medications and supplements before use. Interactions may occur with:
Avoid excessive alcohol while taking sildenafil, as it can lower blood pressure and increase side effect risk. Use with caution if you have any heart-related conditions.
Sildenafil is available by prescription only in the UK.
Don’t let ED affect your confidence or relationships. Buy Sildenafil tablets online today and experience more satisfying erections — securely, discreetly, and from our trusted UK-regulated pharmacy.
✅ Free online consultation✅ Fast UK delivery✅ Discreet packaging✅ GPhC-regulated
now and get back to enjoying intimacy with confidence.
Store Notice: Orders placed after 11:00 AM on Friday, 23 May 2025 will be processed on the next working day, Tuesday, 27 May 2025, due to the bank holiday weekend. Thank you for your understanding.
ShareLikeSildenafil citrate is available by prescription only in the UK.
Reliable and accessible, Sildenafil ED treatment in the UK relies on your dependable pharmacy.
The South Africa Medicines Regulatory Authority (SAMI) is advising patients, healthcare professionals and the public that a new study has found that a new treatment for erectile dysfunction (ED) is no longer considered safe. The study, from the South African Institute of Health and Welfare (SAVIW), shows that the new treatment for ED is a “significant improvement” of the quality of life and the life expectancy of patients.
SAMI is a not-for-profit organisation whose mission is to improve health and wellbeing for all people by offering a safe and effective treatment for erectile dysfunction (ED). In its review, it found that sildenafil, the active ingredient in Viagra, was a “significant improvement” of erectile function (ED) compared to placebo. The new treatment, called sildenafil citrate, “has not only improved patients’ sexual satisfaction and ability to engage in sexual intercourse, but it has also reduced the frequency and duration of sexual activity in patients who have not responded to a placebo or who are taking sildenafil.”
A number of studies in the field of sexual health and sexual medicine have been conducted in the last two decades. The first, published in 2002, was published in the Journal of Sexual Medicine, but it was the only clinical trial that examined the effects of Viagra in adult men and women. The study found that patients who took sildenafil were “significantly more satisfied and less frustrated” than those who did not. The study was not intended to compare sildenafil with placebo, and it did not investigate whether the benefit of sildenafil might be due to a lack of response to a placebo, or other factors.
In 2013, the SAVIW completed an audit of sexual health services and sexual medicine in the South African public sector. In response to the audit, the South Africa Medicines Regulatory Authority (SAMI), which is responsible for ensuring the safety and efficacy of sildenafil, is issuing a new clinical study to assess the safety of sildenafil for the treatment of erectile dysfunction (ED).
SAMI is currently reviewing the findings of the SAVIW study and a new study is being conducted in the United States. The review is part of a larger study that has been funded by the South African Research Foundation (SARF). The new study has been published in the Journal of Sexual Medicine in October 2022.
SAMI’s SAVIW study is currently in the review stage, and there are no definitive conclusions yet.The study was a prospective study of men aged 18 to 55 who were taking sildenafil, and was designed to test the effectiveness of sildenafil for patients who have not responded to a placebo, or have not responded to sildenafil. The study also tested the safety of the treatment for the treatment of ED, using the same criteria as the SAVIW study, and it found that sildenafil was not associated with any serious adverse events (AEs).
SAMI and ARIW are also continuing to conduct research to develop and conduct the same trial to assess the effectiveness of sildenafil. In December 2023, the South African Medicines Authority (SAMCA), the National Research Council and the National Health and Social Care Council were reviewing the SAVIW and ARIW and the review of the data to determine if there was still an important benefit of the study in improving patients’ sexual functioning.
SAMI is conducting a pilot study of sildenafil in men with erectile dysfunction. The study was funded by the South African Research Foundation. The SAVIW study was not intended to compare sildenafil to placebo. The study did not investigate whether the benefit of sildenafil might be due to a lack of response to a placebo, or other factors.
The SAVIW study is now ongoing and the results of the study will be published in the first half of 2024.
In its review of the SAVIW study, it found that sildenafil, the active ingredient in Viagra, was a “significant improvement” of erectile function (ED) compared to placebo.The Viagra of England trial, which is also known as the Viagra of Ireland, is a British oral medicine trial conducted by the National Library of Medicine, which is used by the government in order to investigate the effects of Viagra. The trial began in April 1998 and involved nearly 100 men who were aged between 18 and 70. The men then participated in a series of four clinical tests to determine the causes of their erectile dysfunction. The men were randomly assigned to one of four different groups: Viagra, the active ingredient in Viagra, a placebo, or a drug containing a placebo.
The men were administered the Viagra tablets either as a tablet to the patient or as a placebo. The participants were then asked to take one tablet before sex and to take the tablets twice a day at four different times throughout the four sessions. After the tablets were taken, they were assessed for the presence of a painful erection and sexual desire. The men who took the pills did not have any of the signs and symptoms of erectile dysfunction which were recorded in the patients’ medical records.
The Viagra of England trial is one of the first clinical trials conducted by the National Library of Medicine into the effects of Viagra. The drug is manufactured by the pharmaceutical company Eli Lilly, and was approved for sale in the United States for the treatment of erectile dysfunction. It is sold under the brand name Viagra, and has been available in various forms over the years, including pills, tablets, and injections. The company has been known to have a reputation of producing the most successful pharmaceutical products, and has been successful in marketing the product to the public. The Viagra of England trial was the first in the world to be conducted by the National Library of Medicine. It is a collaboration between the National Library of Medicine and the National Library of Medicine, and was the first in the world to produce a drug, the Viagra of Ireland Trial, that is being studied by researchers at the University of California, San Francisco.
The Viagra of England Trial is a double-blind, placebo-controlled, single-dose, multi-center study designed to study the effect of Viagra on sexual desire in men who were aged between 18 and 70 years. Participants will be randomly assigned to one of four treatment groups: a placebo, the active ingredient in Viagra, a placebo containing a placebo, or a drug containing a placebo. The results of the study will be presented in a public television commercial at the end of the study.
The results of the Viagra of England trial will be presented at the American Sexual Medicine Association (ASMPA) Annual Meeting in Chicago, IL on October 26, 1998. The ASMPA Annual Meeting will be held from October 29 to 30, 1998. The ASMPA Annual Meeting will be held at the University of Chicago and the ASMPA Annual Meeting will be held at the University of Pennsylvania.
The Viagra of England trial is a double-blind, placebo-controlled, single-dose, multi-center study designed to study the effect of Viagra on sexual desire in men who were aged between 18 and 70 years. The participants will be asked to take a tablet before sex and to take the tablets twice a day at four different times throughout the four sessions. The participants who took the pills did not have any of the signs and symptoms of erectile dysfunction which were recorded in the patients’ medical records.
The Viagra of England trial is a clinical trial that is conducted by the National Library of Medicine. It is the first in the world to be conducted by the National Library of Medicine, and is the first in the world to examine the effects of Viagra on erectile dysfunction. It is sold under the brand name Viagra, and has been available in various forms, including pills, tablets, and injections. The company is also known to have a reputation of producing the most successful pharmaceutical products, and has been successful in marketing the product to the public.
Objective:To investigate the effect of sildenafil (Viagra) on the blood flow and the response to the stimulation of nitric oxide (NO) production by pulmonary arterial and cardiac muscle cells in rats. The effect of sildenafil (Viagra) on the responses of cardiac muscle cells to NO was tested using isolated pulmonary arterial and cardiac muscle cells, while the effect of NO on the responses to NO was studied in pulmonary arterial muscle cells. The results of the present study showed that the response of cardiac muscle cells to NO was impaired in rats treated with sildenafil (Viagra) during a period of 6 h of a 24-h continuous infusion of sildenafil (Viagra). This impairment of NO production was not caused by the stimulation of NO synthesis by NO or nitric oxide (NO) and was not caused by the inhibition of NO synthesis by NO donors or nitrates.
Pulmonary arterial and cardiac muscle cells were isolated from normal and experimental rats and cultured in vitro in media containing either sildenafil (Viagra) or NO donors. Pulmonary arterial muscle cells were cultured in media containing either sildenafil (Viagra) or NO donors in vitro. Sildenafil (Viagra) was added to the media of pulmonary arterial muscle cells in vitro and the NO-sensitive cells were cultured in media containing sildenafil (Viagra) in a similar manner to that observed for pulmonary arterial cells. Sildenafil (Viagra) was found to decrease the responses of cardiac muscle cells to NO in vitro (P<0.05) and in vitro (P0.01) (Table ). Sildenafil (Viagra) decreased the responses of cardiac muscle cells to NO in a dose-related manner (Table ). Sildenafil (Viagra) also decreased the responses of cardiac muscle cells to NO in a dose-related manner (PThe effects of sildenafil (Viagra) on NO production were not affected by the activation of NO donors or by the inhibition of NO synthesis by NO donors.Sildenafil (Viagra) decreased the responses of cardiac muscle cells to NO in a dose-related manner (PIn addition, sildenafil (Viagra) decreased the responses of cardiac muscle cells to NO in a dose-related manner (PThe results of the present study demonstrated that the effects of sildenafil (Viagra) on cardiac muscle cells were mediated by the inhibition of NO synthesis. These effects were not caused by the activation of NO donors or nitric oxide (NO) and were not caused by the inhibition of NO synthesis by NO donors or nitrates.Pulmonary arterial muscle cells were isolated from normal and experimental rats and cultured in media containing either sildenafil (Viagra) or NO donors in vitro. Sildenafil (Viagra) was found to decrease the responses of cardiac muscle cells to NO in a dose-related manner (P
Stade de France Pharmacy